Table 3.
Univariate and multivariate COX-regression of overall survival (OS), and disease-free survival (DFS) in HER2-low and HER2-zero patients.
| OS |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HER2-low |
HER2-zero |
Overall |
||||||||||
| univariate analysis |
multivariate analysis |
univariate analysis |
multivariate analysis |
univariate analysis |
multivariate analysis |
|||||||
| Hazard Ratio (95% CI) | p | Hazard Ratio (95% CI) | p | Hazard Ratio (95% CI) | p | Hazard Ratio (95% CI) | p | Hazard Ratio (95% CI) | p | Hazard Ratio (95% CI) | p | |
|
HER2 status low vs zero |
– | – | – | – | – | – | – | – | 0.302(0.144–0.631) | 0.001 | 0.428(0.202–0.908) | 0.027 |
|
ER status positive vs negative |
0.220(0.068–0.716) | 0.012 | 0.082(0.013–0.533) | 0.009 | 0.197(0.045–0.866) | 0.032 | 0.329(0.031–3.529) | 0.358 | 0.173(0.07–0.425) | 0.000 | 0.160(0.041–0.628) | 0.009 |
|
PR status positive vs negative |
0.503(0.163–1.548) | 0.231 | 2.576(0.470–14.123) | 0.276 | 0.221(0.050–0.975) | 0.046 | 0.465(0.042–5.111) | 0.531 | 0.301(0.128–0.706) | 0.006 | 1.425(0.394–5.161) | 0.589 |
|
T stage T4 vs T1-3 |
1.741(0.479–6.330) | 0.400 | 3.526(0.842–14.771) | 0.085 | 1.182(0.336–4.153) | 0.794 | 1.108(0.311–3.948) | 0.874 | 1.464(0.596–3.597) | 0.406 | ||
|
LN status N1-3 vs N0 |
0.483(0.131–1.784) | 0.275 | 0.505(0.130–1.960) | 0.323 | 1.005(0.284–3.561) | 0.994 | 0.961(0.256–3.610) | 0.952 | 0.639(0.259–1.576) | 0.331 | ||
|
Ki-67 >20% vs ≤ 20% |
1.493(0.410–5.445) | 0.543 | 1.335(0.302–5.903) | 0.703 | 1.689(0.643–4.435) | 0.287 | ||||||
|
AR status positive vs negative |
0.997(0.183–5.448) | 0.998 | 0 | 0.998 | 0.357(0.080–1.597) | 0.178 | ||||||
| Age | 1.009(0.949–1.073) | 0.781 | 0.999(0.956–1.044) | 0.960 | 1.005(0.967–1.044) | 0.814 | ||||||
| DFS | ||||||||||||
| HER2-low | HER2-zero | Overall | ||||||||||
| univariate analysis | multivariate analysis | univariate analysis | multivariate analysis | univariate analysis | multivariate analysis | |||||||
| Hazard Ratio (95% CI) | p | Hazard Ratio (95% CI) | p | Hazard Ratio (95% CI) | p | Hazard Ratio (95% CI) | p | Hazard Ratio (95% CI) | p | Hazard Ratio (95% CI) | p | |
|
HER2 status low vs zero |
– | – | – | – | – | – | – | – | 0.573(0.317–1.038) | 0.066 | 0.683(0.326–1.433) | 0.314 |
|
ER status positive vs negative |
0.432(0.205–0.911) | 0.027 | 0.541(0.094–3.113) | 0.492 | 0.672(0.252–1.797) | 0.429 | 1.068(0.232–4.91) | 0.932 | 0.471(0.261–0.847) | 0.012 | 0.890(0.258–3.071) | 0.854 |
|
PR status positive vs negative |
0.600(0.283–1.273) | 0.183 | 0.960(0.155–5.948) | 0.965 | 0.576(0.205–1.621) | 0.296 | 0.549(0.102–2.941) | 0.483 | 0.558(0.306–1.017) | 0.057 | 0.907(0.258–3.186) | 0.879 |
|
Ki-67 >20% vs ≤ 20% |
2.460(0.853–7.100) | 0.096 | 1.504(0.472–4.791) | 0.490 | 1.620(0.372–7.050) | 0.520 | 0.977(0.188–5.070) | 0.978 | 2.313(0.980–5.459) | 0.056 | 2.081(0.685–6.327) | 0.196 |
|
AR status positive vs negative |
0.224(0.052–0.967) | 0.045 | 0.311(0.069–1.412) | 0.130 | 0.244(0.031–1.899) | 0.178 | 0.226(0.069–0.744) | 0.014 | 0.297(0.085–1.033) | 0.056 | ||
|
T stage T4 vs T1-3 |
2.339(1.030–5.312) | 0.042 | 4.126(1.375–12.378) | 0.011 | 1.250(0.360–4.339) | 0.725 | 1.888(0.959–3.719) | 0.066 | 2.431(1.024–5.772) | 0.044 | ||
|
LN status N1-3 vs N0 |
0.699(0.266–1.840) | 0.468 | 1.753(0.401–7.672) | 0.456 | 0.949(0.424–2.123) | 0.898 | ||||||
| Age | 1.016(0.975–1.058) | 0.458 | 0.958(0.920–0.999) | 0.043 | 0.959(0.920–1.000) | 0.050 | 0.986(0.957–1.016) | 0.361 | ||||
OS: overall survival; DFS: disease-free survival; ER: estrogen receptor; PR: progesterone receptor; AR: androgen receptor.